OBJECTIVES: While various monocyte chemokine systems are increased in expression in osteoarthritis (OA), the hierarchy of chemokines and chemokine receptors in mediating monocyte/macrophage recruitment to the OA joint remains poorly defined. Here, we investigated the relative contributions of the CCL2/CCR2 versus CCL5/CCR5 chemokine axes in OA pathogenesis. METHODS: Ccl2-, Ccr2-, Ccl5- and Ccr5-deficient and control mice were subjected to destabilisation of medial meniscus surgery to induce OA. The pharmacological utility of blocking CCL2/CCR2 signalling in mouse OA was investigated using bindarit, a CCL2 synthesis inhibitor, and RS-504393, a CCR2 antagonist. Levels of monocyte chemoattractants in synovial tissues and fluids from patients with joint injuries without OA and those with established OA were investigated using a combination of microarray analyses, multiplexed cytokine assays and immunostains. RESULTS: Mice lacking CCL2 or CCR2, but not CCL5 or CCR5, were protected against OA with a concomitant reduction in local monocyte/macrophage numbers in their joints. In synovial fluids from patients with OA, levels of CCR2 ligands (CCL2, CCL7 and CCL8) but not CCR5 ligands (CCL3, CCL4 and CCL5) were elevated. We found that CCR2+ cells are abundant in human OA synovium and that CCR2+ macrophages line, invade and are associated with the erosion of OA cartilage. Further, blockade of CCL2/CCR2 signalling markedly attenuated macrophage accumulation, synovitis and cartilage damage in mouse OA. CONCLUSIONS: Our findings demonstrate that monocytes recruited via CCL2/CCR2, rather than by CCL5/CCR5, propagate inflammation and tissue damage in OA. Selective targeting of the CCL2/CCR2 system represents a promising therapeutic approach for OA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVES: While various monocyte chemokine systems are increased in expression in osteoarthritis (OA), the hierarchy of chemokines and chemokine receptors in mediating monocyte/macrophage recruitment to the OA joint remains poorly defined. Here, we investigated the relative contributions of the CCL2/CCR2 versus CCL5/CCR5 chemokine axes in OA pathogenesis. METHODS:Ccl2-, Ccr2-, Ccl5- and Ccr5-deficient and control mice were subjected to destabilisation of medial meniscus surgery to induce OA. The pharmacological utility of blocking CCL2/CCR2 signalling in mouse OA was investigated using bindarit, a CCL2 synthesis inhibitor, and RS-504393, a CCR2 antagonist. Levels of monocyte chemoattractants in synovial tissues and fluids from patients with joint injuries without OA and those with established OA were investigated using a combination of microarray analyses, multiplexed cytokine assays and immunostains. RESULTS:Mice lacking CCL2 or CCR2, but not CCL5 or CCR5, were protected against OA with a concomitant reduction in local monocyte/macrophage numbers in their joints. In synovial fluids from patients with OA, levels of CCR2 ligands (CCL2, CCL7 and CCL8) but not CCR5 ligands (CCL3, CCL4 and CCL5) were elevated. We found that CCR2+ cells are abundant in human OA synovium and that CCR2+ macrophages line, invade and are associated with the erosion of OA cartilage. Further, blockade of CCL2/CCR2 signalling markedly attenuated macrophage accumulation, synovitis and cartilage damage in mouse OA. CONCLUSIONS: Our findings demonstrate that monocytes recruited via CCL2/CCR2, rather than by CCL5/CCR5, propagate inflammation and tissue damage in OA. Selective targeting of the CCL2/CCR2 system represents a promising therapeutic approach for OA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Carla R Scanzello; Brian McKeon; Bryan H Swaim; Edward DiCarlo; Eva U Asomugha; Veero Kanda; Anjali Nair; David M Lee; John C Richmond; Jeffrey N Katz; Mary K Crow; Steven R Goldring Journal: Arthritis Rheum Date: 2011-02
Authors: V B Kraus; G McDaniel; J L Huebner; T V Stabler; C F Pieper; S W Shipes; N A Petry; P S Low; J Shen; T A McNearney; P Mitchell Journal: Osteoarthritis Cartilage Date: 2016-04-12 Impact factor: 6.576
Authors: Elizabeth B Kelso; William R Ferrell; John C Lockhart; Iona Elias-Jones; Todd Hembrough; Lynette Dunning; J Alastair Gracie; Iain B McInnes Journal: Arthritis Rheum Date: 2007-03
Authors: Qian Wang; Kazuhiro Onuma; Changhao Liu; Heidi Wong; Michelle S Bloom; Eileen E Elliott; Richard Rl Cao; Nick Hu; Nithya Lingampalli; Orr Sharpe; Xiaoyan Zhao; Dong Hyun Sohn; Christin M Lepus; Jeremy Sokolove; Rong Mao; Cecilia T Cisar; Harini Raghu; Constance R Chu; Nicholas J Giori; Stephen B Willingham; Susan S Prohaska; Zhen Cheng; Irving L Weissman; William H Robinson Journal: JCI Insight Date: 2019-09-19
Authors: P Lorenzo Bozzelli; Tao Yin; Valeria Avdoshina; Italo Mocchetti; Katherine E Conant; Kathleen A Maguire-Zeiss Journal: Glia Date: 2019-05-23 Impact factor: 7.452
Authors: Eric M Schott; Christopher W Farnsworth; Alex Grier; Jacquelyn A Lillis; Sarah Soniwala; Gregory H Dadourian; Richard D Bell; Madison L Doolittle; David A Villani; Hani Awad; John P Ketz; Fadia Kamal; Cheryl Ackert-Bicknell; John M Ashton; Steven R Gill; Robert A Mooney; Michael J Zuscik Journal: JCI Insight Date: 2018-04-19
Authors: L Longobardi; J M Jordan; X A Shi; J B Renner; T A Schwartz; A E Nelson; D A Barrow; V B Kraus; A Spagnoli Journal: Osteoarthritis Cartilage Date: 2018-05-01 Impact factor: 6.576
Authors: Dragos C Dasoveanu; Hyeung Ju Park; Catherine L Ly; William D Shipman; Susan Chyou; Varsha Kumar; David Tarlinton; Burkhard Ludewig; Babak J Mehrara; Theresa T Lu Journal: Sci Immunol Date: 2020-03-20
Authors: Bocun Li; Li Jing; Li Jia; Tan Qian; Chen Jianyi; Huang Zhongsheng; Zhou Xiaohong; Cai Guowei Journal: Exp Biol Med (Maywood) Date: 2020-09-02